{"id":"W4411343965","doi":"10.1002/hon.70094_220","title":"220 | HIGH EFFICACY OF BRIEF BRAF AND MEK COINHIBITION, ALONE AND COMBINED WITH ANTI‐CD20 IMMUNOTHERAPY, IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: A PHASE‐2 TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Celgene; Leukemia and Lymphoma Society of Canada; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); CD20; Immunotherapy; Oncology; Leukemia; Cancer research; Internal medicine; Lymphoma; Cancer; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057983,0.0002754951,0.001534157,0.0002780053,0.00007611831,0.00001365246,0.0001281817,0.0005979721,0.0001337712],"category_scores_gemma":[0.0004711369,0.0001972741,0.00007645116,0.0004810306,0.001131603,0.00005281884,0.000148227,0.0006481288,0.000005119364],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002617229,"about_ca_system_score_gemma":0.004937624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004493649,"about_ca_topic_score_gemma":0.0001052115,"domain_scores_codex":[0.9974832,0.0003410096,0.0008040605,0.0005902246,0.0003045365,0.0004769757],"domain_scores_gemma":[0.9968597,0.002240363,0.0002250323,0.0003707498,0.0001319579,0.0001722191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.853066,0.02420174,0.006942381,0.00304832,0.0008143174,0.01076126,0.001417111,0.000030021,0.05263713,0.01997549,0.01068226,0.01642396],"study_design_scores_gemma":[0.9466257,0.02675178,0.005350041,0.0004693175,0.0001644242,0.001262489,0.0002122163,0.0007486827,0.01364171,0.0008510192,0.003628289,0.0002943366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992309,0.001791867,0.00009740739,0.001449575,0.0001079441,0.001565792,0.000008149679,0.00006252212,0.00260769],"genre_scores_gemma":[0.9973781,0.0006535599,0.0007520872,0.0007214855,0.00003990131,0.00008647682,0.00003382589,0.00002250808,0.000312125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09355968,"threshold_uncertainty_score":0.8759132,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01757900197584383,"score_gpt":0.3244681010151445,"score_spread":0.3068890990393007,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}